abstract: BACKGROUND: In various studies it has been shown that @entity2 enhances the risk for a unfavorable pathological @entity1 stages, higher Gleason scores (GS), positive surgical margins (PSM), and certain perioperative parameters (higher @entity3 , higher length of surgery, higher complication rates) after radical prostatectomy. However, for robot-assisted radical prostatectomy (RARP) there are only a few studies addressing this topic with partially conflicting results. Furthermore, none of these studies actually represents the clinical practice pattern as performed in a European centre. MATERIAL AND METHODS: Beside further clinical and histopathological parameters, also body mass index (BMI) of @entity0 undergoing RARP was recorded. The following categories were registered: BMI of <   25   kg/m  , >=    25-29.9   kg/m  , and >=    30   kg/m   defined as normal weight, overweight, and @entity2 , respectively. The potential correlation between BMI on the one hand and various criteria of aggressive @entity1 biology and specific perioperative parameters on the other hand has been examined on univariate and multivariable analyses. RESULTS: 22.8% (n=79), 59% (n=204), and 18.2% (n=63) of @entity0 of the study group presented with normal weight, overweight, and @entity2 , respectively. Based on the results of various multivariable regression models there was no significant influence of @entity2 on pathological @entity1 stage, pN category, undifferentiated @entity1 growth (>=    GS7b), upgrading, or PSM rates. Furthermore, @entity2 @entity0 showed a significantly higher intraoperative @entity3 and a higher length of surgery, which, however, did not result in a higher rate of grade 3a/b complications according to Clavien-Dindo classification after 90 days. CONCLUSIONS: In the present series of consecutive @entity0 undergoing RARP there was no evidence for a @entity1 biology or a higher complication rate in @entity2 @entity0 .

title: [Influence of Body Mass Index on Histopathological and Intraoperative Criteria in a Consecutive Series of XXXX after Robotic-assisted Radical Prostatectomy].

answer: @entity0


abstract: BACKGROUND: A progressive reduction in the speed and amplitude of repetitive action is an essential component of @entity6 , which is called @entity7 ( @entity7 ). Because @entity7 is specific to @entity2 ( @entity2 ) and is suggested to be associated with @entity4 , its features are of great interest. The aim of this study was, for the first time, to find the neural correlates of @entity7 and to demonstrate whether dopaminergic deficit is correlated with @entity7 . METHODS: We enrolled 12 @entity0 with de novo @entity2 at a tertiary referral hospital. Correlations between @entity7 severity and alterations in gray and white matter were studied. The association between severity of the @entity1 was also analyzed. RESULTS: There was a significant negative correlation between the volumetric changes in the anterior cingulate cortex (ACC) and the inferior semilunar lobule of the cerebellum and the degree of @entity7 . There was a significant correlation between the long association fibers (the superior @entity5 ) connecting the frontal lobes to the temporal, parietal, and occipital lobes and @entity7 . There was a significant negative correlation between @entity7 in the more affected hand and the caudate @entity3 transporter binding in the more affected hemisphere. CONCLUSIONS: Our results suggest that the ACC and the cerebellum (inferior semilunar lobule) are associated with the severity of @entity7 . Taken together with DTI findings, the present study proposes that ACC may have an important role. Our data show that the caudate dopaminergic activity may be related to @entity7 .

title: Neural correlates of progressive reduction of XXXX in de novo @entity2 .

answer: @entity6


abstract: INTRODUCTION AND AIMS: Experiences of @entity3 - @entity2 (BNX) sublingual film injection are not well documented or understood. We examined how @entity0 who inject BNX film seek and share information about this practice, document the methods used to prepare BNX film for injection, and report @entity0 ' experiences of this practice. DESIGN AND METHODS: Interviews were (n   =   16) conducted with @entity0 who indicated that they had injected BNX film since its introduction onto the Australian market. Semistructured interviews were recorded and transcribed. NVivo10 program (QSR International) was used to analyse the data using qualitative description methodology. RESULTS: @entity0 largely reported similar BNX film preparation techniques, although the texture of BNX film during preparation to inject was reported to be unusual (gluggy), and there were many varied accounts associated with the amount of water used. Physical harms reported as associated with injecting BNX film were described (including local and systemic issues); @entity0 reported injecting the film to enhance its immediate effects, yet generally reported that sublingual administration provided longer-lasting effects. DISCUSSION AND CONCLUSIONS: Understanding knowledge acquisition about injecting new formulations of opioid substitution therapy is crucial in developing more effective harm-reduction strategies. Dissemination by peer networks to those who are currently or planning to inject BNX film regarding the 'gelatine like' texture when mixing, using only cold water and double filtering is important to ensure safer injecting practices. Findings from this study highlight the importance of peer networks for the dissemination of harm-reduction information. Introduction of new formulations internationally requires more qualitative studies to inform safer practices. [White N, Flaherty I, Higgs P, Larance B, Nielsen S, Degenhardt L, Ali R, Lintzeris N. Injecting @entity3 - @entity2 film: Findings from an explorative qualitative study. Drug @entity1 Rev 2015].

title: Injecting XXXX - @entity2 film: Findings from an explorative qualitative study.

answer: @entity3


abstract: Runt-homologous molecules are characterized by their DNA binding runt-domain which is highly conserved within bilaterians. The three @entity0 runt-genes are master regulators in cartilage/bone formation and @entity2 . Historically these features evolved in Craniota and might have been promoted by runt-gene duplication events. The purpose of this study was therefore to investigate how many runt-genes exist in the stem species of chordates, by analyzing the number of runt-genes in what is likely to be the closest living relative of Craniota- @entity4 . To acquire further insight into the possible role of runt-genes in early chordate evolution we have determined the number of runt-genes in sea urchins and have analyzed the runt-expression pattern in this species. Our findings demonstrate the presence of a single runt-gene in @entity4 and sea urchin, which makes it highly likely that the stem species of chordates harbored only a single runt-gene. This suggests that runt-gene duplications occurred later in chordate phylogeny, and are possibly also associated with the evolution of features such as @entity2 , cartilage and bone development. In sea urchin embryos runt-expression involves cells of endodermal, mesodermal and ectodermal origin. This complex pattern of expression might reflect the multiple roles played by runt-genes in mammals. A strong runt-signal in the gastrointestinal tract of the sea urchin is in line with runt-expression in the intestine of @entity3 and in the @entity1 gastrointestinal tract, and seems to be one of the phylogenetically ancient runt-expression domains.

title: A single XXXX and sea urchin runt-gene suggests that runt-gene duplications occurred in early chordate evolution.

answer: @entity4


abstract: OBJECTIVES: The aim of the study was to determine whether cardiac pacing reduces @entity4 in older adults with @entity2 (CSH). BACKGROUND: @entity1 causes @entity5 , and symptoms respond to cardiac pacing. There is circumstantial evidence for an association between @entity4 and the syndrome. METHODS: A randomized controlled trial was done of consecutive older @entity0 (>50 years) attending an accident and emergency facility because of a non-accidental fall. @entity0 were randomized to dual-chamber pacemaker implant (paced @entity0 ) or standard treatment (controls). The primary outcome was the number of @entity4 during one year of follow-up. RESULTS: One hundred seventy-five eligible @entity0 (mean age 73 +/- 10 years; 60% @entity0 ) were randomized to the trial: pacemaker 87; controls 88. Falls (without @entity3 ) were reduced by two-thirds: controls reported 669 @entity4 (mean 9.3; range 0 to 89), and paced @entity0 216 @entity4 (mean 4.1; range 0 to 29). Thus, paced @entity0 were significantly less likely to fall (odds ratio 0.42; 95% confidence interval: 0.23, 0.75) than were controls. @entity5 were also reduced during the follow-up period, but there were much fewer @entity5 than @entity4 -28 episodes in paced @entity0 and 47 in controls. Injurious events were reduced by 70% (202 in controls compared to 61 in paced @entity0 ). CONCLUSIONS: There is a strong association between non-accidental @entity4 and cardioinhibitory CSH. These @entity0 would not usually be referred for cardiovascular assessment. Carotid sinus @entity2 should be considered in all older adults who have non-accidental @entity4 .

title: XXXX : a modifiable risk factor for nonaccidental @entity4 in older adults (SAFE PACE).

answer: @entity1


abstract: Single nucleotide polymorphisms (SNPs) may contribute to the malignant process and may show clinicopathological importance as prognostic markers. The multidrug resistance gene @entity4 encodes a membrane transporter which confers cytostatic drug resistance in @entity1 and protects normal tissues from xenobiotics. We analyzed the @entity6 SNP in the @entity4 gene which is associated with altered cellular drug uptake in matched @entity1 and normal tissues of 45 @entity0 suffering from @entity2 . We have developed a highly sensitive matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF- @entity3 ) method to survey the @entity6 polymorphism in PCR-amplified fragments of the @entity4 gene. Thirteen @entity0 were homozygous for C/C (29%), 15 were heterozygous (33%) and 17 were homozygous for @entity5 (38%). None of the @entity1 samples showed an altered SNP compared to their matched normal tissue samples. As analyzed by the Kruskall-Wallis test, none of the clinicopathological parameters was significantly associated with homo- or heterozygosity. The combination of PCR, allele-specific primer extension reactions and MALDI-TOF- @entity3 offers a promising alternative method for genotyping the @entity4 gene especially for heterozygous situations. The inherent advantages of MALDI-TOF- @entity3 based genotyping include its high molecular resolution, high signal-to-noise-ratios and reproducibility, combined with an excellent sensitivity. As none of the @entity1 samples showed an altered state compared to their matched normal tissue samples, the genotypic frequency of this polymorphism seems not to be altered during colorectal tumorigenesis.

title: @entity4 single nucleotide polymorphism @entity6 in normal colorectal tissue and XXXX detected by MALDI-TOF mass spectrometry.

answer: @entity2


abstract: BACKGROUND: The onset of clinical @entity4 in @entity0 with @entity5 usually marks the existence of irreversible and progressive @entity2 . Prevention of @entity3 ought to take place in earlier stages, mostly in the outpatient setting and in close collaboration with general practitioners (GPs). This study aims to evaluate the prevalence and the clinical stage of @entity5 and to screen for progression factors in the regional community referred to the outpatient department of the nephrology unit of the Mons. DiMiccoli Hospital in Barletta; it is intended as the first phase of a collaborative project for the prevention of @entity5 . METHODS: Our team asked for the collaboration of GPs within the geographic area referring to our outpatient department. This led to the institution of a working group aimed at interrelating primary with hospital care in the setting of nephrology. The clinical data of @entity1 @entity0 as well as their codified personal data were classified by GPs and subsequently processed by the nephrology team. The glomerular filtration rate was estimated by means of the abbreviated MDRD study equation. Finally, the cumulative prevalence of known risk factors for @entity5 progression was assessed in a subgroup of 201 @entity1 @entity0 . RESULTS: Within the whole group of screened subjects from the regional community (21,314), the prevalence of @entity1 was 3.54%, and the rates of personal and clinical features did not show any substantial differences from the ones recorded in Italy as a whole. In the subgroup of 201 @entity1 @entity0 , the cumulative frequency of progression factors for @entity5 showed a relevant percentage of subjects with clinical and laboratory features deviating from the targets proposed by current guidelines, thus justifying the adoption of specific prevention plans. CONCLUSIONS: This study shows the feasibility and the advantages of setting up a stable collaboration between hospital and primary care in order to improve the diagnosis and prevention of @entity2 . Identification of the most frequently deviant progression factors provides the primary target for the prevention of @entity2 in @entity1 @entity0 .

title: [Hospital-primary care teamwork in nephrology: 'preventive' epidemiology of XXXX ].

answer: @entity5


abstract: INTRODUCTION: @entity6 ( @entity6 ) is a rare clinical syndrome caused by an enlarging, aggressive corticotroph pituitary @entity2 that can occur following bilateral adrenalectomy performed in the treatment of refractory @entity3 ( @entity3 ). @entity1 respond poorly to currently available therapeutic options, which include surgery, radiotherapy, pharmacotherapy, and chemotherapy. They are a challenging problem in neurosurgical practice. The aim of this work was to evaluate the early and long-term results of microsurgery in a single surgeon's series of @entity0 with @entity6 . MATERIAL AND METHODS: During the period from January 2000 to December 2005, 10 @entity0 with @entity6 underwent surgery. The authors analysed surgical outcomes in the @entity6 group of seven @entity0 and three @entity0 with the mean age of 47.99 years (range 39-66, SD    8.47 years). @entity6 was diagnosed based on clinical signs and symptoms, especially @entity7 of the skin, elevated serum @entity9 levels, and @entity1 growth. Parasellar extension of the @entity2 was assessed in both groups according to Knosp's and @entity8 . Pituitary function and radiographs were evaluated in the early postoperative period, 30 days after the operation, and during follow-up. Histological examination was based on the WHO (2004) criteria. RESULTS: According to the criteria for @entity6 remission, five @entity0 (50%) were cured. No perioperative mortality was reported. Three @entity0 developed @entity10 and two @entity0 developed @entity5 . There was one case of postoperative @entity11 . One @entity0 was diagnosed with @entity4 . CONCLUSIONS: Transsphenoidal microsurgical removal of @entity4 is a safe and effective treatment of @entity6 . (Endokrynol Pol 2015; 66 (6): 504-513).

title: Outcomes in pituitary surgery in XXXX - therapeutic pitfalls.

answer: @entity6


abstract: BACKGROUND: A pharmacoinvasive (PI) strategy for early presenting ST-segment elevation @entity2 nominally reduced 30-day @entity5 and @entity3 compared with @entity1 ( @entity1 ). We evaluated whether @entity4 size (IS) was related to this finding. METHODS AND RESULTS: Using the peak cardiac biomarker in @entity0 randomized to PI versus @entity1 within the Strategic Reperfusion Early After @entity2 (STREAM) trial, IS was divided into 3 groups: small ( <=2 times the upper limit normal [ULN]), medium (>2 to  <=5 times the upper limit normal) and large (>5 times the upper limit normal). The association between IS and 30-day shock and @entity3 was subsequently examined. Data on 1701 of 1892 (89.9%) @entity0 randomized to PI (n=853, 50.1%) versus @entity1 (n=848, 49.9%) within STREAM were evaluated. A higher proportion of @entity1 @entity0 had a large IS (PI versus @entity1 : small, 49.8% versus 50.2%; medium, 56.9% versus 43.1%; large, 48.4% versus 51.6%; P=0.035), despite comparable intergroup ischemic times for each reperfusion strategy. As IS increased, a parallel @entity6 and @entity3 occurred in both treatment arms, except for the small IS group. The difference in shock and @entity3 in the small IS group (4.4% versus 11.6%, P=0.026) in favor of PI likely relates to higher rates of @entity2 with the PI strategy (72.7% versus 54.3%, P=0.005). After adjustment, a trend favoring PI persisted in this subgroup (relative risk 0.40, 95% CI 0.15 to 1.06, P=0.064); no difference in treatment-related outcomes was evident in the other 2 groups. CONCLUSION: A PI strategy appears to alter the pattern of IS after ST-segment elevation @entity2 , resulting in more medium and fewer large @entity4 compared with @entity1 . Despite a comparable number of small @entity4 , PI @entity0 in this group had more aborted @entity2 and less 30-day shock and @entity3 . CLINICAL TRIAL REGISTRATION: URL: http://ClinicalTrials.gov. Unique identifier: NCT00623623.

title: XXXX Size, Shock, and @entity3 : Does Reperfusion Strategy Matter in Early Presenting @entity0 With ST-Segment Elevation @entity2 ?

answer: @entity4


abstract: We evaluated the prevalence of @entity3 in @entity0 who have taken anorectic medications. Two-dimensional echocardiograms with color flow Doppler were recorded in 200 consecutive @entity0 referred to a major metropolitan hospital for evaluation of cardiac function because of a history of anorectic medication use. Each @entity0 filled out a questionnaire at the time of the visit or through telephone contact. Each echocardiogram was reviewed by 2 observers. The degree of @entity3 was graded by a consensus of both observers. Significant @entity3 was defined as at least moderate @entity2 ( @entity2 ) or at least mild @entity1 ( @entity1 ), as recommended by the Food and Drug Administration and Centers for Disease Control and Prevention. For all @entity0 having taken anorectic drugs, there was a 5% prevalence of at least moderate @entity2 , a 12% prevalence of at least mild @entity1 , and a 16% prevalence of significant @entity2 and/or @entity1 . @entity0 with significant @entity1 and/or @entity2 were older than those without significant @entity3 (49+/-12 vs 44+/-11 years, p = 0.03). @entity0 with significant @entity2 and/or @entity1 had a longer exposure duration (8 vs 6 months, p = 0.049) to anorectic drugs. There was no difference in weight loss between those with and without significant regurgitation (p = NS). The 2 largest subgroups were @entity0 who took the @entity4 - @entity6 combination (n = 127) and those who took @entity5 alone (n = 42). The prevalence of significant @entity2 and @entity1 was 5% and 9% for the @entity4 - @entity6 group and 0% and 14% for the @entity5 group, respectively. There was also a high subthreshold level of @entity2 and @entity1 in these @entity0 .

title: Echocardiographic prevalence of mitral and/or @entity1 in XXXX exposed to either @entity4 - @entity6 combination or to @entity5 .

answer: @entity0


abstract: BACKGROUND: Low @entity6 ( @entity6 ) @entity5 ( @entity5 ) in vein grafts and stents. We studied the causal relationship between @entity6 and @entity5 formation in stents by locally increasing @entity6 with a flow divider (Anti-Restenotic Diffuser, Endoart SA) placed in the center of the stent. METHODS AND RESULTS: In 9 @entity1 fed a high- @entity3 diet for 2 months to induce @entity4 , 18 stents were implanted in the right and left external iliac arteries (1 stent per vessel). Lumen diameters were measured by quantitative angiography before and after implantation and at 4-week follow-up, at which time, macrophage accumulation and interruption of the internal elastic lamina was determined. Cross sections of stent segments within the @entity7 ( @entity7 ), outside the @entity7 (S[minus] @entity7 ), and in corresponding segments of the contralateral control stent (SCTRL) were analyzed. Changes in @entity6 induced by the @entity7 placement were derived by computational fluid dynamics. Computational fluid dynamics analysis demonstrated that @entity6 increased from 0.38 to 0.82 N/m2 in the @entity7 immediately after @entity7 placement. This augmentation of shear stress was accompanied by (1) lower mean late luminal loss by quantitative angiography ([minus]0.23+/-0.22 versus [minus]0.58+/-0.30 mm, P=0.02), (2) reduction in @entity5 (1.48+/-0.58, 2.46+/-1.25, and 2.36+/-1.13 mm2, P<0.01, respectively, for @entity7 , S[minus] @entity7 , and SCTRL), and (3) a reduced @entity0 score and a @entity2 score. Increments in shear stress did not change the relationship between injury score and @entity5 or between @entity0 score and @entity5 . CONCLUSIONS: The newly developed @entity7 flow divider significantly increases @entity6 , and this local increment in @entity6 is accompanied by a local reduction in @entity5 and a local reduction in @entity0 and injury. The present study is therefore the first to provide direct evidence for an important modulating role of shear stress in in-stent @entity5 .

title: Augmentation of XXXX inhibits @entity5 after stent implantation: inhibition through @entity0 ?

answer: @entity6


abstract: BACKGROUND: The immediate initiation and high quality of @entity1 ( @entity1 ) are pivotal to improving @entity0 outcome after @entity2 . Although cardiorespiratory monitoring could shorten the time to recognize the onset of @entity2 , little is known about how monitoring and the misinterpretation of monitor readings could impair the initiation of @entity1 . In this study, we assessed the speed of initiation and quality of @entity1 in simulated monitored and nonmonitored pediatric @entity2 . METHODS: Sixty residents frequently involved in the care of critically ill @entity0 were randomly assigned to either the intervention (monitoring) group or the control (nonmonitoring) group. @entity0 of both groups performed @entity1 in 1 of 2 clinically identical, unwitnessed simulated @entity2 scenarios. Although in 1 scenario cardiorespiratory monitoring (i.e., electrocardiogram) was attached, the other scenario reflected a nonmonitored @entity2 . Time to first chest compression was chosen as the primary outcome variable. Adherence to resuscitation guidelines and subjective performance ratings were secondary outcome variables. RESULTS: @entity0 in the monitoring group initiated chest compressions significantly later than those in the nonmonitoring group (91    36 vs 71  26 seconds, hazard ratio, 0.26; 95% confidence interval, 0.14-0.49, P < 0.001). Six members of the monitoring group did not start chest compression within 5 minutes. Furthermore, adherence to the guidelines was better in the nonmonitoring group. @entity0 who were previously involved in @entity1 training did not show better performance. CONCLUSIONS: The presence of cardiorespiratory monitoring significantly delayed or even prevented the initiation of chest compressions and impaired the quality of @entity1 in simulated pediatric @entity2 . Based on these data, specific training should be conducted for exposed personnel.

title: The Impact of Monitoring on the Initiation of Cardiopulmonary Resuscitation in XXXX : Friend or Foe?

answer: @entity0


abstract: UNASSIGNED: Drugs activating the sigma-1 (  1) chaperone protein are anti- @entity3 and neuroprotective in neurodegenerative pathologies like @entity1 ( @entity1 ). Since these so-called   1 receptor (  1R) agonists modulate cholinergic and glutamatergic systems in a variety of physiological responses, we addressed their putative additive/synergistic action in combination with cholinergic or glutamatergic drugs. The selective   1 agonist @entity8 , or the non-selective   1 drug @entity9 was combined with the @entity6 inhibitor @entity7 or the @entity4 receptor antagonist @entity5 in the nontransgenic @entity0 model of @entity1 -like @entity2 induced by intracerebroventricular injection of oligomeric Ab25-35 peptide. Two behavioral tests, spontaneous alternation and passive avoidance response, were used in parallel and both protective and symptomatic effects were examined. After determination of the minimally active doses for each compound, the combinations were tested and the combination index (CI) calculated. Combinations between the   1 agonists and @entity7 showed a synergic protective effect, with CI<1, whereas the combinations with @entity5 showed an antagonist effect, with CI>1. Symptomatic effects appeared only additive for all combinations, with CI=1. A pharmacological analysis of the @entity8 + @entity7 combination revealed that the synergy could be due to an inter-related mechanism involving a7 nicotinic ACh receptors and   1R. These results demonstrated that   1 drugs do not only offer a protective potential alone but also in combination with other therapeutic agents. The nature of neuromodulatory molecular chaperone of the   1R could eventually lead to synergistic combinations.

title: Protection by sigma-1 receptor agonists is synergic with XXXX , but not with @entity5 , in a @entity0 model of amyloid-induced @entity2 .

answer: @entity7


abstract: BACKGROUND: Many regimens of @entity1 - @entity4 chemotherapy have proven activity in @entity0 with advanced @entity5 ( @entity5 ). However, the optimal dose and schedule still have to be established. @entity0 AND METHODS: We conducted a phase II study with administration of @entity4 50 mg/m(2) on days 1 and 8 and @entity1 800 mg/m(2) on days 2, 9 and 15. This schedule was selected to optimise the synergism between the two drugs and reduce @entity2 due to high dose @entity4 . RESULTS: Thirty-six chemo-naive @entity0 with stage IIIA, IIIB or IV @entity5 entered the study (26 @entity0 , 10 @entity0 ; median age 58 years, range 29-74). Twenty @entity0 achieved a partial response: 7 out of 10 stage IIIA @entity0 , 7 out of 13 stage IIIB @entity0 and 6 out of 13 stage IV @entity0 . On intent-to-treat basis, the overall response rate (RR) was 58% (95% confidence interval, 42-74%). Ninety percent of stage IIIA @entity0 and 46% of stage IIIB @entity0 received adjuvant surgery or radiotherapy. Overall median duration of response was 28 weeks (range 6-147 weeks). For stage IIIA, IIIB and IV @entity0 , these numbers were 91, 13 and 23 weeks, respectively. One-year survival was 49% with 90%, 23% and 42% for stage IIIA, IIIB and IV @entity0 , respectively. The main @entity2 was myelosuppression. WHO grades 3 and 4 @entity6 occurred in 67% of @entity0 , whereas 61% experienced grade 3 or 4 @entity3 . Although hematological @entity2 was clinically tolerable, it frequently led to omission of @entity1 administration on day 15. The incidence of @entity7 was very low. CONCLUSION: This regimen of @entity4 on days 1 and 8 and @entity1 on days 2, 9 and 15 induced a high RR in @entity0 with advanced NCSLC. Frequent omission of @entity1 day 15 is a limitation of this schedule. This should be an important factor in a practical approach to decide on the most optimal schedule of the @entity4 plus @entity1 combination.

title: Combination of XXXX and @entity4 for advanced @entity5 : a phase II study with emphasis on scheduling.

answer: @entity1


abstract: BACKGROUND: Immunotherapies targeting cellular immunity are currently approved for treatment of @entity5 , @entity8 , and @entity4 . Studies on the immunogenicity and immune responsiveness of @entity2 are limited, therefore, it remains unclear to what extent T-cell-based immunotherapy holds promise for pediatric @entity2 . PROCEDURE: A new @entity7 cell line (M3-9-M) was derived from an @entity10 ( @entity10 ) occurring in a C57BL/6 @entity3 transgenic for hepatocyte growth factor and heterozygous for mutated @entity6 . @entity2 and @entity1 derived from M3-9-M were studied for similarities to @entity0 @entity10 , and for immunogenicity and immune responsiveness. RESULTS: Primary and @entity1 develop after orthotopic injection of M3-9-M into immunocompetent C57BL/6 @entity3 , which mirror @entity0 @entity10 with regard to histology, gene expression, and metastatic behavior. Whole cell vaccination using irradiated M3-9-M cells or M3-9-M-pulsed dendritic cells (DC)-induced @entity2 -specific T-cell responses that prevent @entity2 growth following low-dose @entity2 injection, and slow @entity2 growth following higher doses. Administration of anti- @entity11 moAbs to deplete @entity9 (+) @entity11 (+)FOXP3(+) regulatory T cells prior to @entity2 vaccination enhanced the potency of the @entity2 vaccine. Adoptive immunotherapy with M3-9-M primed T cells plus DC-based vaccination resulted in complete eradication of day 10 M3-9-M derived @entity2 . CONCLUSIONS: M3-9-M derived @entity3 @entity10 is immunogenic and immunoresponsive; regulatory T cells contribute to immune evasion by @entity3 @entity7 . Adoptive immunotherapy with DC vaccination can eradicate low @entity2 burdens. Future work will seek to identify the @entity2 -associated antigens that mediate protective and therapeutic immunity in this model.

title: XXXX @entity7 is immunogenic and responsive to T-cell-based immunotherapy.

answer: @entity3


abstract: BACKGROUND: @entity3 is a potent antioxidant and is involved in many metabolic activities including collagen biosynthesis. In the present investigation, @entity3 and lipid @entity7 were monitored in the blood and liver samples during the progression of experimentally induced @entity6 . METHODS: @entity2 was induced by intraperitoneal injections of @entity4 ( @entity5 ) on three consecutive days of every week over a period of 21 days. The progression of @entity1 was assessed by histopathological examination and by monitoring of the collagen content of the liver tissue. @entity3 and lipid @entity7 were monitored in both blood and liver samples on days 0, 7, 14, and 21 after the start of @entity5 administration. The liver total protein was also measured during the investigation. RESULTS: Histopathological examination demonstrated @entity0 , @entity1 , and early @entity1 during @entity5 treatment. The collagen content increased four-fold on the 21st day of investigation. Lipid @entity7 were elevated significantly in both blood and liver specimens on days 7, 14, and 21. A drastic decrease was observed in the @entity3 concentrations in both liver and blood samples on all days after the start of @entity5 administration. Liver total protein concentrations were significantly reduced during @entity5 administration. CONCLUSIONS: The exact mechanism of the decrease of @entity3 during @entity5 -induced @entity6 is not clear. The most probable reason for the decreased blood and liver @entity3 during @entity5 -induced @entity6 is the increased utilization of @entity3 for free radical scavenging in order to reduce the highly elevated oxidative stress.

title: @entity3 concentrations in XXXX -induced @entity6 in rats.

answer: @entity4


abstract: @entity6 cotransporters (KCCs) play a fundamental role in epithelial cell function, both in the context of ionic homeostasis and also in cell morphology, cell division and locomotion. Unlike other ubiquitously expressed KCC isoforms, expression of @entity7 is widely considered to be restricted to neurons, where it is responsible for maintaining a low intracellular @entity5 concentration to drive hyperpolarising postsynaptic responses to the inhibitory neurotransmitters @entity3 and @entity4 . Here we report a novel finding that @entity7 is widely expressed in several @entity0 @entity1 cell lines including the @entity1 cell line (SiHa). Membrane biotinylation assays and immunostaining showed that endogenous @entity7 is located on the cell membrane of @entity0 cells. To elucidate the role of @entity7 in cervical tumuorigenesis, @entity0 cells with stable overexpression or knockdown of @entity7 were employed. Overexpression of @entity7 had no significant effect on cell proliferation but dramatically suppressed cell spreading and stress fibre organization, while knockdown of @entity7 showed opposite effects. In addition, @entity2 ( @entity2 )-induced cell migration and invasiveness were significantly increased by overexpression of @entity7 . @entity7 -induced cell migration and invasion were not dependent on @entity7 transport function since overexpression of an activity-deficient mutant @entity7 still increased @entity2 -induced cell migration and invasion. Moreover, overexpression of @entity7 significantly diminished the number of focal adhesions, while knockdown of @entity7 increased their number. Taken together, our data establish that @entity7 expression and function are not restricted to neurons and that @entity7 serves to increase cervical tumourigenesis via an ion transport-independent mechanism.

title: The potassium- XXXX cotransporter 2 promotes @entity1 cell migration and invasion by an ion transport-independent mechanism.

answer: @entity5


abstract: BACKGROUND: Intraoperative pleural and interstitial PDT accompanying resection may reduce peripheral micrometastatic foci and preclude lobectomy when applied to hilar lesions. MATERIALS AND METHODS: Fourteen beagles were used to determine the safety and histologic changes resulting from PDT. Photosensitizers HPPH (0.3 mg/kg) or @entity4 (2.0 mg/kg) were administered i.v. 48 hours prior to thoracotomy and light delivery. At thoracotomy interstitial or pleural light was given. They underwent necropsy at eight and 30 days. RESULTS: The significant toxicitities occurred with @entity1 using high dose HPPH (15 _ 30 J/cm2) including pyrexia, elevated WBC and @entity3 , and @entity2 . However, using single beam pleural surface treatment all light doses for HPPH and @entity4 (5-40 J/cm2) were tolerated with depths of treatment effect up to 10 mm with HPPH. CONCLUSION: Histologic and clinical changes associated with interstitial and @entity1 were acceptable after dosimetry was adjusted. PDT holds promise as an adjuvant treatment for @entity0 pulmonary metastases.

title: Photodynamic therapy for XXXX pulmonary metastases: a preclinical toxicity study.

answer: @entity0


abstract: UNASSIGNED: In @entity0 with @entity4 ( @entity4 ), @entity3 ( @entity3 ) is associated with poorer treatment adherence and higher readmission and mortality rates. Previous studies suggest that @entity6 ( @entity6 ) could impair cognitive function. This study sought to assess the association between permanent @entity6 (permAF) and @entity3 in @entity0 with @entity4 . We evaluated cognitive function in 881 @entity0 with stable @entity4 (73    11  years, 44% @entity0 , 48% with preserved ejection fraction) using the Mini-Mental State Examination test (n  = 876) and the Pfeiffer's Short Portable Mental Status Questionnaire (n  = 848). @entity3 was defined as a Mini-Mental State Examination score <24 or Short Portable Mental Status Questionnaire (errors) >2. The independent association between permAF and @entity3 was assessed by binary logistic regression analysis. A total of 295 @entity0 (33.5%) had @entity3 , in 5.1% of cases moderate/severe. @entity0 with permAF had more frequently any degree of @entity3 (43% vs 31%), and moderate/severe @entity3 (8% vs 5%). In the multivariate analysis, @entity3 was associated with permAF (odds ratio 1.54, 95% C.I. 1.05 to 2.28), an older age, female gender, @entity1 , @entity5 , @entity2 , New York Heart Association class III/IV, and lower systolic blood pressure. No interaction was found for @entity6 and @entity3 between @entity0 with reduced and preserved ejection fraction. In conclusion, the presence of permAF is independently associated with @entity3 in @entity0 with @entity4 , both with reduced and preserved ejection fraction. Given the clinical impact of @entity3 in the @entity4 population, active assessment of cognitive function is particularly warranted in @entity0 with @entity4 with permAF.

title: Effect of Permanent @entity6 on Cognitive Function in @entity0 With XXXX .

answer: @entity4


abstract: UNASSIGNED: @entity5 increases the risk of development of @entity1 @entity3 . @entity9 is an enzyme dominantly expressed during inflammatory reactions and seems to play a critical role in tumorigenesis. Our aim was to assess the @entity9 expression in four types of @entity1 @entity3 : breast, colorectal, nasopharyngeal, and @entity7 , of Tunisian @entity1 . The level of @entity9 was measured by RT-QPCR in @entity3 specimens. We showed that the expression of @entity9 was higher in breast compared to @entity4 , whereas in @entity7 , the level of @entity9 expression was low. Significant associations were found when comparing the @entity9 expression in @entity3 pairs such as @entity7 versus colorectal (p   <   0.0001), colorectal versus nasopharyngeal (p   =   0.0072), and @entity7 versus breast (p   <   0.0001). Furthermore, @entity9 expression correlated with the Breslow thickness, Clark level, and histological subtype in @entity7 , while in @entity6 , significant association was seen with age at diagnosis, TNM, @entity2 , response to treatment, and expression of @entity8 . Furthermore, the expression of @entity9 correlated with @entity3 size, TNM, @entity3 location, and histological type in @entity4 , and with @entity3 size, @entity3 stage, SBR grade, and triple negative cases in @entity0 . On the other hand, immunohistochemistry analysis shows that the expression of @entity9 is observed in the stroma and @entity3 cells as well. Overall, our results highlight that @entity9 is a reliable marker for advanced stage and aggressive behavior for the four types of @entity3 and might be a potential promising therapeutic target.

title: Quantitative measurement of @entity9 expression in @entity7 , nasopharyngeal, colorectal, and XXXX of Tunisian @entity1 : comparative study and clinical significance.

answer: @entity0


abstract: We present a 21 year-old @entity0 with @entity10 ( @entity10 ) suffering from @entity3 and frequent long bone @entity5 (approximately 1 or 2 @entity5 /year) who was treated with i.v. @entity7 for 3 years. @entity10 is a rare @entity1 characterized by severe widespread @entity4 leading to pathological @entity5 and @entity9 . @entity2 ( @entity2 ) (g/cm2) was determined at lumbar spine and femur neck by dual energy X-ray absorptiometry. @entity2 studies were also performed in her parents and 18 year-old brother who were phenotypically normal. Within 2 months of the first @entity7 treatment the @entity0 reported considerable decrease in @entity3 and improved mobility. During the treatment period no important side effects and no recurrent @entity5 were reported. There were substantial increases in @entity2 , T score and z-score at both lumbar spine and femoral neck during therapy. Baseline lumbar spine @entity2 increased from 0.416 to 0.489 g/cm2 and femoral neck @entity2 increased from 0.455 to 0.532 g/cm2 after 3 years. Although her parents and brother did not have any history of @entity5 , @entity2 measurements revealed that her parents were @entity8 and her brother was osteoporotic. We demonstrated that @entity7 therapy seems to be safe and beneficial in both @entity6 in @entity0 with @entity10 . Moreover, the present study clearly indicates that bone density studies and LRPS gene screening for mutations should be performed in phenotypically normal family members of @entity0 with @entity10 .

title: Effects of 3 years of intravenous @entity7 treatment on bone markers and bone mineral density in a @entity0 with @entity10 ( XXXX ).

answer: @entity10


abstract: UNASSIGNED: Numerous studies have reported an association between fine particulate matter (PM2.5) and @entity0 health. Often these relationships are influenced by environmental factor that varies spatially and/or temporally. To our knowledge, there are no studies in Canada that have considered energy generation and fuel sales as PM2.5 effects modifiers. Determining exposure and disease-specific risk factors over space and time is crucial for disease prevention and control. In this study, we evaluated the association of PM2.5 with @entity1 , @entity3 , and @entity2 ( @entity2 ) incidence in Canada. Then we explored the impact of the energy generation and fuel sales on association changes. We fit an age-period-cohort as the study design, and we applied an over-dispersed Poisson regression model to estimate the risk. We conducted a sensitivity analysis to explore the impact of variation in clean energy rates and fuel sales on outcomes changes. The study included 117 health regions in Canada between 2007 and 2014. Our findings showed strong association of PM2.5 with @entity1 , @entity3 , and @entity2 incidence. A two-year increase of 10 g/m(3) in PM2.5 was associated with an increased risk of 5.34% (95% CI: 2.28%; 12.53%) in @entity1 incidence, 2.24% (95% CI: 0.93%; 5.38%) in @entity3 incidence, and 8.29% (95% CI: 3.44%; 19.98%) in @entity2 incidence. Our sensitivity analysis findings suggest higher risks of @entity1 , @entity3 and @entity2 incidence when there is low clean energy generation. On the other hand, we found lower risk when we considered high rate of clean energy generation. For example, considering only @entity1 incidence, we found that the risk in health regions with low rates of clean electricity is approximately 700% higher than the risk in health regions with high rates of clean electricity. Furthermore, our analysis suggested that the risk in regions with low fuel sales is 66% lower than the risk is health regions with low rates of clean electricity. Our study provides support for the creation of effective environmental health public policies that take into account the risk factors present in Canadians health regions.

title: Association of PM2.5 with XXXX , @entity3 , and high blood pressure incidence in Canada: A spatiotemporal analysis of the impacts of the energy generation and fuel sales.

answer: @entity1


abstract: OBJECT: Linear accelerator (LINAC)-based stereotactic radiosurgery (SRS) is a treatment option for @entity0 with @entity4 in whom brain @entity1 have developed. Very limited data are available on treating @entity0 with >= 5 lesions. The authors sought to determine the effectiveness of SRS in @entity0 with >= 5 @entity4 brain @entity1 . METHODS: A retrospective analysis of @entity4 treated with SRS in a single treatment session for >= 5 lesions was performed. Magnetic resonance imaging studies were reviewed post-SRS to evaluate local control (LC). Disease progression on imaging was defined using the 2009 Response Evaluation Criteria in @entity2 (RECIST). Survival curves were calculated from the date of brain @entity1 diagnosis or the date of SRS by using the Kaplan-Meier (KM) method. Univariate and multivariate analysis (UVA and MVA, respectively) were performed using the Cox proportional-hazards model. RESULTS: The authors identified 149 metastatic @entity3 treated in 28 @entity0 . The median @entity0 age was 60.5 years (range 38-83 years), and the majority of @entity0 (24 [85.7%]) had extracranial @entity1 . Four @entity0 (14.3%) had received previous whole-brain radiotherapy (WBRT), and 11 (39.3%) had undergone previous SRS. The median planning target volume ( @entity5 ) was 0.34 cm3 (range 0.01-12.5 cm3). Median follow-up was 6.3 months (range 1-46 months). At the time of treatment, 7% of @entity0 were categorized as recursive partitioning analysis (RPA) Class I, 89% as RPA Class II, and 4% as RPA Class III. The rate of local failure was 11.4%. Kaplan-Meier LC estimates at 6 and 12 months were 91.3% and 82.2%, respectively. A @entity5 volume>= 0.34 cm3 was a significant predictor of local failure on UVA (HR 16.1, 95% CI 3.2-292.6, p<0.0001) and MVA (HR 14.8, 95% CI 3.0-268.5, p=0.0002). Sixteen @entity0 (57.1%) were noted to have distant failure in the brain with a median time to failure of 3 months (range 1-15 months). Nine @entity0 with distant failures received WBRT, and 7 received additional SRS. Median overall survival (OS) was 9.4 and 7.6 months from the date of brain @entity1 diagnosis and the date of SRS, respectively. The KM OS estimates at 6 and 12 months were 57.8% and 28.2%, respectively, from the time of SRS treatment. The RPA class was a significant predictor of KM OS estimates from the date of treatment (p=0.02). @entity0 who did not receive WBRT after SRS treatment had decreased OS on MVA (HR 3.5, 95% CI 1.1-12.0, p=0.03), and @entity0 who did not receive WBRT prior to SRS had improved OS (HR 0.11, 95% CI 0.02-0.53, p=0.007). CONCLUSIONS: Stereotactic radiosurgery for >= 5 lesions appears to be effective for selected @entity0 with @entity4 , offering excellent LC. This is particularly important for @entity0 as new targeted systemic agents are improving outcomes but still have limited efficacy within the central nervous system.

title: Potential role for LINAC-based stereotactic radiosurgery for the treatment of 5 or more radioresistant @entity4 brain XXXX .

answer: @entity1


abstract: CONTEXT: Immunohistochemical staining for @entity6 ( @entity6 ) is a useful ancillary technique for diagnosing @entity5 ( @entity2 ) in histologic specimens. Although similar results have been obtained on aspirate smears, to our knowledge the utility of @entity6 immunolocalization in cell block preparations as an adjunct to fine-needle aspiration diagnosis of @entity2 has not been examined. OBJECTIVE: The purpose of this study was to determine whether @entity6 immunostaining of cell block preparations of thyroid aspirates is a useful ancillary technique for diagnosing @entity2 . MATERIALS AND METHODS: Using a monoclonal antibody to @entity6 and a standard avidin- @entity4 complex technique, immunostaining was performed on paraffin-embedded cell blocks of 57 cases with the following cytologic diagnoses: (a) @entity2 (20 cases); (b) atypical cytology, cannot exclude @entity2 (19 cases); and (c) nonneoplastic thyroid (18 cases). The staining reaction in each case was graded on the basis of percentage of epithelial cells stained (1+, <10%; 2+, <10%-50%; 3+, >50). Tissue follow-up was available in all cases. RESULTS: Nineteen (95%) of 20 cases with an unequivocal diagnosis of @entity2 were positive for @entity6 (3+). Tissue follow-up confirmed @entity2 in all 20 cases. Of the 19 cases with a diagnosis of atypical cytology, cannot exclude @entity2 , 7 (37%) cases displayed 3+ immunostaining and subsequent excision confirmed @entity2 in all 7 cases. The remaining 12 cases with 1+ immunostaining included surgically confirmed @entity7 (6 cases), @entity1 (2 cases), @entity3 (3 cases), and @entity2 (1 case). The follicular cells in 18 cases with a cytologic diagnosis of nonneoplastic thyroid showed 1+ immunostaining. Histologic follow-up of these cases confirmed the nonneoplastic cytologic diagnoses. CONCLUSIONS: @entity6 immunostaining of cell block preparations of thyroid aspirates serves as a useful tool for the diagnosis of @entity2 . Strong immunostaining (3+) for @entity6 aids in accurate diagnosis of @entity0 in cytomorphologically equivocal cases of @entity2 .

title: @entity6 immunolocalization in cell block preparation of thyroid aspirates. An adjunct to fine-needle aspiration diagnosis of XXXX .

answer: @entity5


abstract: BACKGROUND: Circadian variation in @entity1 of @entity3 has been demonstrated in animal and @entity0 studies. @entity0 with @entity4 are frequently prescribed @entity3 . Altered pharmacokinetics of @entity3 are predictive of @entity2 . AIM: To investigate whether the time of day of @entity7 administration modulates renal excretion of @entity6 and @entity2 in @entity0 with @entity4 . To determine whether circadian rhythms are disrupted in @entity0 with @entity4 during hospital admission. METHODS: @entity0 (age 5-18years) with @entity4 scheduled for @entity6 therapy were randomly allocated to receive @entity6 at 0800 or 2000h. Serum @entity6 levels were drawn at 1h and between 3.5 and 5h post-infusion between days 5 and 9 of therapy. @entity5 levels were measured serially at intervals from 1800h in the evening until 1200h on the next day. Circadian rhythm was categorised as normal when dim light @entity5 onset was demonstrated between 1800 and 2200h and/or peak @entity5 levels were observed during the night. Weight and spirometry were measured at the start and end of the therapy. Urinary biomarkers of @entity1 ( @entity11 , @entity9 , @entity10 , @entity8 and CysC) were assayed at the start and end of the course of @entity6 . RESULTS: Eighteen @entity0 were recruited to the study. There were no differences in renal clearance between the morning and evening groups. The increase in urinary @entity11 was greater in the evening dosage group compared to the morning group (mean difference, 0.73ng/mg; 95% CI, 0.14 to 1.32; p=0.018). There were no differences in the other urinary biomarkers. There was normal circadian rhythm in 7/11 @entity0 (64%). CONCLUSIONS: Renal elimination of @entity6 was not affected by the time of day of administration. Urinary @entity11 raises the possibility of greater nephrotoxicity with evening administration. Four @entity0 showed disturbed circadian rhythm and high @entity5 levels (ClinicalTrials.gov NCT01207245).

title: The pharmacokinetics and @entity2 of morning vs. evening XXXX dosing for pulmonary exacerbations of @entity4 : A randomised comparison.

answer: @entity6


abstract: @entity10 is a well-recognized complication of the Fontan procedure, occurring in up to 24% of @entity0 . Because of the loss of chylous fluid into the gut lumen, @entity9 results as well as @entity6 and hypogammaglobulinaemia. In some cases, dilated lymphatics in the intestinal serosa or mesentery also rupture, causing @entity7 . Standard medical and cardiac surgical interventions are generally ineffective and the condition is frequently lethal. We report a case of intractable and life-threatening @entity7 and chylothorax in a 14-year-old @entity0 , associated with @entity10 and @entity9 after a Fontan procedure for @entity4 . The condition was refractory to all standard medical therapies, including dietary modifications, diuretics, corticosteroid therapy, albumin infusions, @entity5 , heparin, bowel rest, and parenteral nutrition. Cardiac surgery to optimize her hemodynamic status was also ineffective and large volume pleural and ascitic fluid losses continued. Having exhausted all other therapeutic modalities, @entity2 -dextran scintigraphy was performed to assess the extent of intestinal protein loss and the potential for surgical intervention. Scintigraphy suggested localized protein loss from the proximal jejunum and subsequent segmental resection was effective. Postoperatively, @entity1 and @entity3 resolved, and there was no evidence of @entity8 . Growth has accelerated and the @entity0 has entered puberty. There is mild persistent intestinal protein loss requiring diuretic therapy. Ascites or @entity3 are absent, and the @entity0 remains well >2 years after surgery. @entity10 post-Fontan procedures has traditionally been ascribed to hemodynamic factors such as raised systemic venous pressure, which would predispose to a generalized intestinal lesion. However, in this case, scintigraphy demonstrated a localized, surgically correctible lesion. To our knowledge, this is the first reported case of the use of @entity2 -dextran scintigraphy for this indication and of successful partial small bowel resection in such a case.

title: Successful resection of localized @entity10 post-Fontan: role of XXXX -dextran scintigraphy.

answer: @entity2


abstract: UNASSIGNED: The Tabapu   breed is a beef @entity0 Brazilian breed known for its @entity2 and desirable characteristics for tropical conditions. However, this is a newly formed breed and few studies have been conducted regarding genetic parameters and genetic trends for its reproductive traits. The objective of the present study was to estimate the genetic parameters, genetic trends, and relative selection efficiency for weaning weight adjusted to 210 d of age (W210), age at first calving (AFC), average calving interval (ACI), first calving interval (CI1), and @entity1 ( @entity1 ) among Tabapu   beef @entity0 . Pedigree data on 15,241 Tabapu   animals born between 1958 and 2011 and phenotype records from 7,340 @entity0 born between 1970 and 2011 were supplied by the National Association of Breeders and Researchers (Associa    o Nacional de Criadores e Pesquisadores). Analysis through the least squares method assisted in defining the fixed effects that were considered within the models. The estimates for the genetic parameters were obtained through the REML, using a multitrait animal model. The likelihood ratio test applied for W210 was significant ( < 0.05) for the inclusion of maternal additive genetic and permanent environmental effects in the model. Genetic trends were calculated through linear regression of the EBV of the animals, according to the year of birth. The heritability estimates obtained ranged from 0.04    0.03 for CI1 to 0.25    0.05 for W210. The genetic correlations ranged from 0.004    0.19 for W210-AFC and 0.93    0.12 for ACI-CI1. The genetic trend was significant ( < 0.05) and favorable for CI1 and the maternal genetic effect of W210 and was significant ( < 0.05) and unfavorable for AFC, ACI, and @entity1 . The @entity1 could be used in the selection index to assist the breeding goal of improved productive and reproductive performance. The genetic trends indicated small and unfavorable genetic changes for AFC, ACI, and @entity1 in light of the recent implementation of a genetic breeding program for this breed.

title: Estimates of genetic parameters and genetic trends for reproductive traits and weaning weight in Tabapu   XXXX .

answer: @entity0


abstract: BACKGROUND: The @entity2 challenge test correlates well with a @entity0 's peak diurnal intraocular pressure (IOP) measurement. We aimed to investigate the effect that a functioning trabeculectomy has on the @entity2 challenge test. DESIGN: Non-randomized prospective clinical trial evaluating a diagnostic test. @entity0 : Thirteen @entity0 were recruited through @entity1 clinics at the Flinders Medical Centre. Of these, seven required surgical management with trabeculectomy surgery, whilst the remainder were managed medically. METHODS: @entity0 underwent IOP measurement, and then two drops of @entity2 2% solution were instilled into the study eye of each @entity0 . After 45   min, IOP was reassesed. A positive challenge test was considered to be a rise in IOP of greater than 3   mmHg. Changes from baseline were determined and compared between groups. Twelve months later, this test was then repeated in all @entity0 . MAIN OUTCOME MEASURE: Change in IOP after @entity2 challenge. RESULTS: Following the @entity2 challenge, IOP increased by 9.2   mmHg (SD 2.8) (100% positive) for medically managed @entity0 and 7.2   mmHg (SD 2.0) (100% positive) for surgically managed @entity0 (P   =   0.18). The surgically managed group then underwent trabeculectomy surgery. Twelve months later, the @entity2 challenge was repeated. Following the repeat @entity2 challenge, IOP increased by 7.2   mmHg (SD 2.3) for medically managed @entity0 and 0.3   mmHg (SD 1.3) for surgically managed @entity0 (P   <   0.0001). The medically managed group remained 100% positive, whilst the surgically manage group became 0% positive (Fisher Exact P   =   0.044). CONCLUSIONS: A @entity1 @entity0 with a positive @entity2 challenge will show a negative challenge result when re-tested following trabeculectomy surgery.

title: XXXX challenge testing becomes negative following successful trabeculectomy surgery.

answer: @entity2


abstract: Vocal @entity5 are increasingly recognized in @entity0 with @entity6 ( @entity6 ). We describe a @entity0 with limb-onset @entity6 who developed @entity11 . A 74-year-old Japanese male consulted our clinic with a 6-month history of @entity3 in both arms. His family history was unremarkable. There were @entity10 and mild @entity1 and both arms. In the legs, muscle strength was almost normal but widespread @entity10 were present. All tendon reflexes were hypoactive and pathological reflexes were absent. Thereafter, he developed @entity3 and showed increased eating time. Babinski sign was positive bilaterally at this stage. The forced vital capacity dropped from 90% at the initial evaluation to 62% of the predicted value 14 months later. Two years after disease onset, the @entity0 developed @entity8 with hoarseness and had difficulty clearing his throat of phlegm. Laryngoscopy demonstrated severe @entity11 on both sides, particularly in the abductor muscles possibly leading to obstruction. Tracheotomy was performed because of the risk that the @entity0 could @entity9 to @entity2 . A review of the literature suggests that severe @entity4 could be a prelude to @entity7 in @entity6 . Follow up by laryngoscopic examination is necessary.

title: [A case of @entity6 with bilateral XXXX necessitating tracheotomy].

answer: @entity11


abstract: BACKGROUND: The @entity1 of @entity4 to bone is associated with a substantial increase in bone matrix turnover. Matrix metalloproteinases (MMPs) play roles in both normal bone remodeling and invasion and @entity1 of @entity4 . This study was designed to determine the role of MMP activity in @entity4 that has metastasized to bone. METHODS: Single @entity0 fetal bone fragments were implanted subcutaneously in immunodeficient @entity3 . Four weeks later, @entity5 @entity0 @entity4 cells were injected directly into some of the implants, and daily treatment was begun with batimastat (a broad-spectrum MMP inhibitor). There were six @entity3 (i.e., six implants) in each of four experimental arms: bone alone with and without batimastat and bone injected with @entity5 cells with and without batimastat. Bone implants were harvested after 14 days of treatment and analyzed for MMP expression, bone histomorphometry, osteoclast counts, blood vessel density, and @entity2 cell proliferation and apoptosis. Complementary data were obtained from bone biopsy samples from @entity0 and a bone organ coculture system. All statistical tests were two-sided. RESULTS: MMPs were detected in @entity2 and stromal cells of clinical specimens and experimental bone implants. In vivo, MMP inhibition reduced the number of osteoclasts per millimeter in @entity5 -injected implants-from 8.2 (95% confidence interval [CI] = 7.9 to 8.5) to 3.0 (95% CI = 2.3 to 3.7) (P =.006). In addition, it prevented degradation of marrow trabeculae within the bone implants (cross-sectional area of implant occupied by mineralized trabeculae: untreated implant = 29.1% [95% CI = 27.1% to 31.1%], @entity5 -injected implant = 14.0% [95% CI = 10.9% to 17.1%] [P =.005 versus untreated], and batimastat-treated @entity5 -injected implant = 27.2% [95% CI = 22.4% to 32.0%] [P =.03 versus @entity5 injected alone]). MMP inhibition reduced proliferating @entity2 cells from 20.8% (95% CI = 19.9% to 21.7%) to 7.4% (95% CI = 5.2% to 9.6%) (P =.006), without affecting angiogenesis or apoptosis. In vitro, MMP inhibition had no toxic effect on @entity5 cells but prevented calcium release from bone fragments cocultured with @entity5 cells. CONCLUSIONS: MMP activity appears to play an important role in bone matrix turnover when @entity4 cells are present in bone. Bone matrix turnover and metastatic @entity2 growth appear to be involved in a mutually supportive cycle that is disrupted by MMP inhibition.

title: Matrix metalloproteinase activity, bone matrix turnover, and @entity2 cell proliferation in XXXX bone @entity1 .

answer: @entity4


abstract: Dendritic cells (DC) are the initiators of immune responses and are present in most tissues in vivo. To generate myeloid DC from monocytes (MoDC) in vitro the necessary cytokines are @entity4 ( @entity4 ) and @entity5 ( @entity5 ). Using degenerated primers delineated from other species and rapid amplification of cDNA ends reverse transcription-polymerase chain reaction (RACE RT-PCR), the cDNA of @entity3 (eq.) @entity4 was cloned and found to have a point deletion at the 3'-end of eq. @entity4 , resulting in a 24- @entity2 extended open reading frame not described in any species thus far. For differentiating eq.MoDC, monocytes were stimulated with eq. @entity4 and eq. @entity5 . The eq.MoDC was analysed by both light and electron microscopy and by flow cytometry and mixed lymphocyte reaction. The eq.MoDC obtained had the typical morphology and function of DC, including the ability to stimulate allogeneic T cells in a mixed lymphocyte reaction. In contrast to the @entity0 system, however, monocytes had to be differentiated for 6-7 days before immature DC were obtained. Our data also indicate that lipopolysaccharide or poly(I:C) alone are not sufficient to confer the full phenotypic transition into mature DC. Thus our study contributes to understanding the heterogeneity of immunity and adds important information on the @entity3 immune system, which is clearly distinct from those of @entity1 or @entity0 .

title: Monocyte-derived dendritic cells from @entity3 differ from dendritic cells of @entity0 and XXXX .

answer: @entity1


abstract: PURPOSE: The objective of the study was to describe the occurrence of @entity7 and @entity3 in @entity0 with @entity4 ( @entity4 ) treated with second-line @entity5 in a real-world setting. METHODS: This multicenter, prospective, observational study was conducted in France by physicians with experience of treatment of @entity0 with @entity4 . @entity0 aged >= 18  years who received @entity5 after first-line antivascular endothelial growth factor ( @entity1 ) therapy were included in the study. The primary safety assessments were occurrence of @entity7 (in terms of severity, event dates, and therapeutic management) and noninfectious @entity2 (in terms of detection methodology, severity, event dates, and therapeutic management). RESULTS: Between September 2010 and August 2012, 284 @entity0 were enrolled at 77 centers, of whom, 274 received @entity5 therapy. Most @entity0 had @entity4 of clear cell histology (88%), and most of them (84%) received first-line @entity6 . In total, 40% of @entity0 experienced treatment-related @entity7 , and 15% of @entity0 experienced @entity3 . Most of them had a single episode. The incidence of grade 3 @entity7 and @entity3 were 8 and 3%, respectively. Mean time to the first episode was 27  days for @entity7 and 72  days for @entity3 from treatment initiation. @entity7 and @entity3 resulted in treatment discontinuations in 2 and 7% of @entity0 , respectively. The primary first-episode treatment was mouthwash (86%) for @entity7 and corticosteroids (65%) for @entity3 . CONCLUSIONS: This study confirms that @entity7 and @entity3 are commonly associated with @entity5 use. Both adverse events were rarely severe and were managed easily and efficiently.

title: A prospective observational study on the evaluation of @entity5 -related adverse events in XXXX after first-line anti- @entity1 therapy: the AFINITE study in France.

answer: @entity4


abstract: BACKGROUND, AIMS: Oral @entity2 -reducing bacteria are involved in several clinical categories of @entity3 . The aim of this cross-sectional study was to compare the presence of @entity2 -reducing bacteria (SRB) with other putative pathogens including spirochetes, @entity6 , @entity5 , @entity4 , and @entity7 in periodontal lesions. METHOD: Periodontal SRB were detected by enrichment culture and compared with a microscopic spirochete count (n=168). Species-specific oligonucleotide probes directed against the 16S rRNA were employed to determine the presence of A. actinomycetemcomitans, @entity4 , @entity5 , and @entity7 (n=55). RESULTS: A significant positive correlation was observed between the presence of SRB and the proportions of spirochetes in @entity1 , although the 2 bacterial groups also occurred separately. SRB tended to be negatively correlated with the presence of A. actinomycetemcomitans. In contrast, all pockets with SRB harbored either @entity7 , or both @entity7 and @entity5 (12/14) before therapy. Interestingly, the combination of SRB with @entity4 occurred in 32% of the periodontal pockets before treatment. After initial periodontal therapy, the prevalence of this combination was reduced to 2% of the sites, and to 25% of the sites in recall @entity0 . CONCLUSION: The presence of SRB was positively correlated with @entity7 , @entity5 , and @entity4 in periodontal lesions. These suspected pathogens form a complex strongly associated with destructive @entity3 .

title: XXXX -reducing bacteria in relation with other potential periodontal pathogens.

answer: @entity2


abstract: Two experiments were conducted at the Delta Research and Extension Center in Stoneville, MS, during 2011 and 2012 to determine the impact of water management practices on the efficacy of insecticidal seed treatments targeting @entity0 water weevil, Lissorhoptrus oryzophilus Kuschel. Larval densities and yield were compared for plots treated with labeled rates of @entity1 , @entity3 , and @entity2 and an untreated control. In the first experiment, plots were subjected to flood initiated at 6 and 8 wk after planting. Seed treatments significantly reduced larval densities with the 8-wk flood timing, but not the 6-wk flood timing. Overall, the treated plots yielded higher than the control plots. In the second experiment, the impact of multiple flushes on the efficacy of insecticidal seed treatments was evaluated. Plots were subjected to zero, one, or two flushes with water. All seed treatments reduced larval densities compared with the untreated control. Significantly fewer larvae were observed in plots that received one or two flushes compared with plots that did not receive a flush. All seed treatments resulted in higher yields compared to the untreated control in the zero and one flush treatments. When two flushes were applied, yield from the @entity1 and @entity2 treated plots was not significantly different from those of the control plots, while the @entity3 treated plots yielded significantly higher than the control. These data suggest that time from planting to flood did not impact the efficacy of seed treatments, but multiple flushes reduced the efficacy of @entity1 and @entity2 .

title: Impact of Water Management on Efficacy of Insecticide Seed Treatments Against @entity0 Water Weevil (Coleoptera: Curculionidae) in Mississippi XXXX .

answer: @entity0


abstract: BACKGROUND: A low @entity4 ( @entity3 ) serum concentration at @entity1 diagnosis might be associated with worse survival. We prospectively studied the prognostic value of @entity3 at diagnosis and during follow-up. METHODS: MelanCohort is a cohort of invasive @entity1 patients. Serum @entity3 was measured by mass spectrometry and standardized on month of blood drawn, age, sex, and body mass index (BMI). Role of @entity3 levels and risk of relapse was analyzed in a Cox proportional hazards model adjusting for age, sex, BMI, and American Joint Committee on Cancer (AJCC) stage. All statistical tests were two-sided. RESULTS: One thousand one hundred seventy-one @entity0 were included. @entity3 levels at diagnosis (median = 49.0 nmol/L) were inversely correlated with prognostic factors such as AJCC stage (P < .001 Kruskal-Wallis), Breslow's thickness (P < .001 Spearman correlation), and @entity2 (P < .001 Kruskal-Wallis), but not with risk of relapse. Changes in @entity3 levels during follow-up were associated with worse prognosis: With a third quartile Q3 of average change per year (-0.30 to 4.60 nmol/L/Y) used as reference, hazard ratios for the first, second, and fourth quarters were 1.94 (95% confidence interval [CI] = 1.36 to 2.76), 1.23 (95% CI = 0.85 to 1.78), and 1.61 (95% CI = 1.14 to 2.28), respectively. In sensitivity analyses, no changes were observed either by AJCC stage, number of @entity3 measures performed, or by @entity3 level at baseline. No evidence of reverse causation was identified. Analyses performed on overall survival yielded similar results. CONCLUSIONS: We show that @entity3 variation during follow-up is an independent @entity1 prognostic marker, but not its level at diagnosis. Previously reported associations between low @entity3 level at diagnosis and poor prognosis seem to be due to insufficient adjustment for prognostic factors.

title: Prognostic Value of XXXX Levels at Diagnosis and During Follow-up in @entity1 @entity0 .

answer: @entity4


abstract: AIM: This study was designed to answer the question of whether multifocal steady-state pattern-reversal electroretinography (ERG) is capable of detecting @entity1 . METHOD: Sixteen @entity0 (28 eyes) and ten normal subjects (20 eyes) were examined. Multifocal pattern ERGs were recorded with the RETIscan system and DTL electrodes. We stimulated with a steady-state checkerboard pattern reversal (three reversals during 171 ms sweep length, congruent with 17.5 reversals/s). The multifocal pattern ERG amplitudes were evaluated using discrete Fourier transformation (DFT) across three reversals. In cases of advanced @entity2 , the DFT-calculated amplitudes were combined in hemispheres and checked for correlations with corresponding @entity1 . In all binocularly examined @entity0 , side comparisons ("worse" eye vs "better" eye), and interindividual comparisons ( @entity2 vs normal) were carried out. RESULTS: In interindividual comparisons and interocular side comparisons, significant @entity3 were seen in the foveal records. No topographical correlation between multifocal pattern ERG amplitudes and @entity1 could be found. CONCLUSIONS: In @entity1 , multifocal steady-state pattern-reversal ERG using the present stimulation was significantly reduced in its foveal records but seems to be incapable of detecting them topographically.

title: [Multifocal steady-state pattern-reversal electroretinography in @entity2 XXXX ].

answer: @entity0


abstract: OBJECTIVE: To generate phage-displayed anti-idiotypic antibody single chain variable fragments (anti-Id ScFv) MG7 to monoclonal antibody directed against @entity2 so as to lay a foundation for developing anti-Id ScFv vaccine of the @entity0 . METHODS: Balb/c @entity1 were immunized i.p. with purified MG7 monoclonal antibody conjugated with keyhole limpet hemocyanin. mRNA was isolated from the spleens of immunized @entity1 . Heavy and light chain genes (VH and VL) of antibody were amplified separately and assembled into ScFv genes with a specially constructed linker DNA by RT-PCR. The ScFv genes were ligated into the phagemid vector pCANTAB5E and the ligated sample was transformed into competent @entity3 TG1. The transformed cells were infected with M13KO7 helper phage to yield recombinant phage, which displayed ScFv fragments as a fusion with gene 3 protein on the tips of M13 phage. After four rounds of panning with monoclonal antibody MG7, the MG7-positive clones were selected with the enzyme-linked immunosorbent assay (ELISA) from the enriched phages. The types of the anti-Id ScFv displayed on the selected phage clones were primarily identified by competition ELISA. RESULTS: The VH, VL and ScFv DNAs were about 340, 320 and 750 bp respectively. Twenty-four MG7-positive clones were selected from 40 enriched phage clones. Five of the 24 clones displayed beta or gamma type anti-Id ScFv. CONCLUSION: The anti-Id ScFv frangments to MG7 monoclonal antibody can be successfully selected by recombinant phage antibody technique, which paves a way for the study of prevention and cure of @entity2 using anti-Id ScFv.

title: [Production of phage-displayed anti-idiotypic antibody single chain variable fragments to MG7 monoclonal antibody directed against XXXX ].

answer: @entity2


abstract: BACKGROUND/AIMS: Thrombolysis for @entity3 is more effective in smokers. Our aim was to determine whether smokers treated by intravenous (i.v.) rt-PA for @entity4 have better outcomes. METHOD: Comparison of smokers and non-smokers for baseline characteristics and month-3 outcome in @entity0 treated by i.v. rt-PA for @entity4 in Lille, France, and Belgrade, Serbia. The primary outcome was a modified Rankin scale (mRS) 0-1 or similar to the pre- @entity1 mRS. Secondary outcomes were an mRS 0-2 and @entity2 . RESULTS: We included 459 @entity0 (255 @entity0 ; median age 65 years, interquartile range 52-76; 135 smokers). Smokers were younger (median 53 vs. 70 years, p < 0.0001) and had less severe @entity1 (median NIHSS 10 vs. 14, p < 0.0001). At month 3, they were more likely to have an mRS 0-1 [odds ratio (OR) 1.75; 95% confidence interval (CI) 1.17-2.62], or an mRS 0-2 (OR 2.90; 95% CI 1.86-4.52) and less likely to be dead (OR 0.28; 95% CI 0.13-0.61). Smoking was not independently associated with outcome after adjustment for case mix [adjusted OR ((adj)OR) 0.86; 95% CI 0.52-1.43]. CONCLUSION: Smoking does not independently influence the outcome in @entity0 treated by rt-PA for @entity4 . The better outcome in smokers is the consequence of differences in case mix.

title: Influence of differences in case mix on the better outcome of smokers after intravenous thrombolysis for XXXX .

answer: @entity4


abstract: OBJECTIVES: This study sought to compare the impact of primary coronary angioplasty and thrombolytic therapy for @entity2 ( @entity2 ) on 1-month @entity4 size and microvascular perfusion. BACKGROUND: The effect of the reperfusion strategies of primary coronary angioplasty and thrombolytic therapy on microvascular integrity still remains to be determined. METHODS: Sixty-two consecutive @entity0 with a first @entity2 , undergoing intravenous @entity5 ( @entity5 ) therapy (32 @entity0 , Group I) or primary angioplasty (30 @entity0 , Group II), were studied. Only @entity0 with 1-month Thrombolysis in @entity2 (TIMI) flow grade 2 or 3 were selected for the study. @entity0 in whom primary angioplasty was unsuccessful or those with clinical evidence of failed reperfusion were excluded. Microvascular perfusion was assessed at 1 month by intracoronary injection of sonicated microbubbles. Contrast score index (CSI) and wall motion score index (WMSI) were derived using qualitative methods. RESULTS: At baseline there were no significant differences between groups for age, risk factors, time to hospital presentation, Killip class on admission, prevalence of multivessel disease or anterior @entity4 site, @entity4 area extension before reperfusion, peak @entity3 kinase levels and postinfarction treatment. Conversely, significant differences between groups were found at follow-up for percent residual @entity4 (70 +/- 12 vs 36 +/- 14 [mean +/- SD], p = 0.0001), CSI (1.02 +/- 0.4 vs. 1.49 +/- 0.5, p = 0.0003) and WMSI (1.67 +/- 0.3 vs. 1.45 +/- 0.3, p = 0.015). In particular, in the subset of @entity0 with TIMI grade 3 flow, a perfusion defect occurred in one or more segments subtended by the IRA in 72% of Group I versus 31% of Group II @entity0 (p < 0.00001) and in 27% of Group I versus 8% of Group II segments (p < 0.00001). CONCLUSIONS: The present study shows, in a highly selected cohort with successful IRA recanalization, that primary angioplasty is more effective than thrombolysis in preserving microvascular flow and preventing extension of @entity1 at 1-month after @entity2 .

title: XXXX therapy versus primary coronary angioplasty: impact on myocardial tissue perfusion and regional function 1 month after uncomplicated @entity2 .

answer: @entity5


abstract: ABSTRACT Purpose: The acute phase protein, a1-acid glycoprotein, is expressed in the lung, and influences endothelial cell function. We asked whether it might regulate angiogenesis in @entity0 lung microvascular endothelia. MATERIALS AND METHODS: a1-acid glycoprotein was isolated from human serum by HPLC ion exchange chromatography. Its effects on endothelial cell functions including capillary-like tube formation on Matrigel, migration in a wounding assay, chemotaxis in a modified Boyden chamber, adhesion, and transendothelial flux of the permeability tracer, @entity3 -albumin, were tested. RESULTS: a1-acid glycoprotein dose-dependently inhibited capillary-like tube formation without loss of cell viability. At >= 0.50  mg/mL, it inhibited tube formation >70%, and at 0.75  mg/mL, >97%. a1-acid glycoprotein dose- and time-dependently restrained EC migration into a wound as early as 2  hours, and in washout studies, did so reversibly. It was inhibitory against @entity1 and @entity2 -driven migration but failed to inhibit chemotactic responsiveness. When a1-acid glycoprotein was added to preformed tubes, it provoked their almost immediate disassembly. As early as 15 minutes, it induced @entity4 without endothelial cell-cell disruption. It exerted a biphasic effect on cell adhesion to the Matrigel substrate. At lower concentrations (0.05-0.25  mg/mL), it increased cell adhesion, whereas at higher concentrations (>= 0.75  mg/mL) decreased adhesion. In contrast, it had no effect on transendothelial (14)C-albumin flux. CONCLUSION: a1-acid glycoprotein, at concentrations found under physiological conditions, rapidly inhibits endothelial cell capillary-like tube formation that may be explained through diminished cell adhesion to the underlying matrix and/or reversibly decreased cell migration.

title: a1-Acid glycoprotein disrupts capillary-like tube formation of XXXX lung microvascular endothelia.

answer: @entity0


abstract: OBJECTIVE: To evaluate the long-term results of @entity0 surgically treated for metastatic @entity4 ( @entity4 ) with a unique pancreatic secondary localization to assess the importance of radical treatment in this rare group of @entity0 . @entity0 AND METHODS: This is a retrospective monocentric study including 20 surgically treated @entity0 between 1997 and 2012 for a unique pancreatic @entity1 of a @entity4 . The main objective was to evaluate the outcome after surgical resection. RESULTS: Twenty @entity0 were followed up for a @entity4 . The M/F ratio was 1.2. The average age of onset of @entity2 was 57.05    7.78  years. Two @entity0 who had synchronous pancreatic @entity1 and 18 @entity0 who had metachronous @entity1 appeared after an average of 130    59  months (24-240 months). The average size of the metastases was 20    11.6  mm. @entity3 was unique in all @entity0 , with 35% of @entity0 having multiple lesions of the pancreas. All @entity0 underwent a pancreatic resection of @entity1 . Histologic examination confirmed the location of a secondary @entity4 in all @entity0 . Median follow-up after pancreatectomy was 69  months (1-150 months). Disease-free survival at 2  years was 60%. Overall survival rates at 2 and 4  years were 79% and 72%, respectively. There was no difference found between @entity0 with multiple and unique pancreatic metastases in overall survival. CONCLUSION: Unique pancreatic @entity1 of @entity4 is rare. The literature on this subject is limited. Surgical resection might be an option and can be associated with long-term disease-free intervals in highly selected @entity0 .

title: @entity3 from XXXX : outcome of an aggressive approach.

answer: @entity4


abstract: PURPOSE: To determine the genomic organization of the @entity2 @entity3 gene and to evaluate if mutations in @entity3 are responsible for the @entity1 phenotype in the @entity2 ( @entity2 ) mutants niezerka (nie(m743)) and mikre oko (mok(m632)). METHODS: Overlapping fragments were PCR amplified from genomic DNA isolated from homozygous mutant embryos and wild-type siblings (sibs). Amplicons were sequenced and sequence data assembled into contigs. Genomic organization was determined by alignment of contigs with published cDNA sequences and @entity2 genomic sequence from Sanger and Ensembl databases. Linkage analysis used DNA from mapping panels of single homozygous mutant animals with mixed genetic backgrounds. RESULTS: The analysis indicated that the @entity2 @entity3 gene consisted of three exons and 2 introns, and spans 3.8 kb of genomic DNA. The splice junctions were all located within the coding region. Highly repetitive sequences present in non-coding regions of @entity3 and extended tetra- @entity0 repeats in intronic regions were associated with sequence variation between different strains. Homozygous mok(m632) or nie(m743) mutants and their respective wild-type sibs, showed identical patterns of heterozygosity and sequence variations within each line. No mutation in @entity3 were identified in homozygous mok(m632) or nie(m743). Consistent with the absence of identified mutations, linkage analysis excluded linkage of the mutant phenotypes to @entity3 . CONCLUSIONS: Despite the presence of sequence variations in their respective genetic backgrounds, within each line the sequence of @entity3 was identical. Consistent with the absence of mutations, further analysis excluded linkage of the mutant phenotypes to @entity3 . Analysis is in progress to map these loci and identify the genes responsible for the @entity1 phenotype in these mutant lines.

title: Genomic organization of @entity2 cone-rod homeobox gene and exclusion as a candidate gene for XXXX in niezerka and mikre oko.

answer: @entity1


abstract: UNASSIGNED: OBJECT The study aim was to examine the effect of gradually reducing the opening pressure on symptoms and signs in the shunt treatment of @entity2 ( @entity2 ). METHODS In this prospective double-blinded, randomized, controlled, double-center study on @entity0 with @entity2 , a ventriculoperitoneal shunt with an adjustable Codman Medos Valve was implanted in 68 @entity0 randomized into 2 groups. In 1 group (the 20-4 group) the valve setting was initially set to 20 cm @entity1 and gradually reduced to 4 cm @entity1 over the course of the 6-month study period. In the other group (the 12 group), the valve was kept at a medium level of 12 cm @entity1 during the whole study period. All @entity0 were clinically evaluated using 4 tests preoperatively as well as postoperatively at 1, 2, 3, 4, and 6 months. The test scores between the 2 groups (20-4 and 12) were compared for each clinical evaluation. RESULTS Fifty-five @entity0 (81%) were able to complete the study. There were no significant differences between the 2 groups (20-4 and 12) preoperatively or at any time postoperatively. Both groups exhibited significant clinical improvement after shunt insertion at all valve settings compared with the preoperative score, with the greatest improvement observed at the first postoperative evaluation. The clinical improvement was significant within the first 3 months, and thereafter no significant improvement was seen in either group. CONCLUSIONS Gradual reduction of the valve setting from 20 to 4 cm @entity1 did not improve outcome compared with a fixed valve setting of 12 cm @entity1 . Improvement after shunt surgery in @entity2 @entity0 was evident within 3 months, irrespective of valve setting.

title: A double-blind randomized trial on the clinical effect of different shunt valve settings in XXXX .

answer: @entity2


abstract: BACKGROUND: @entity3 @entity1 is an important public health issue in the Amazon region, and it accounts for approximately 84  % of cases of the disease. Migration across the border between Brazil and French Guiana contributes to the maintenance of the disease. The aim of this study was to evaluate the therapeutic and parasitological responses of @entity0 with @entity3 @entity1 treated with @entity2 and @entity4 in the socio-environmental context of cross-border interactions between Brazil and French Guiana. The factors controlled were diagnostic agreement, adherence, adjustment of @entity4 doses for @entity0 weight, and quality of the drugs used. METHODS: A prospective study was conducted in 2011 with 103 individuals aged 10-60  years with a positive diagnosis of @entity3 treated with @entity2 (10  mg base/kg on the first day, followed by 7.5  mg/kg on the second and third days) and @entity4 for 7  days, who were followed for 28  days. The @entity4 doses were adjusted for the @entity0 ' weight. A number of factors were determined: epidemiological characteristics, origin of @entity0 , signs and symptoms, initial parasitaemia and parasitaemia clearance time, blood concentrations of @entity2 and @entity4 , quality of anti-malarial drugs and diagnostic agreement. RESULTS: Ninety-five @entity0 were followed for 28  days. There was a 100  % agreement in microscopic diagnosis between field laboratory and reference centre. The adhesion to the treatment was 100  %. Of these @entity0 , 32.6  % received a weight-adjusted dose of @entity4 . The @entity2 and @entity4 tablets were consistent with the optimal quality limits for @entity0 consumption. The investigated @entity0 achieved optimal blood exposure to anti-malarial drugs. The parasitological and therapeutic response was adequate in 99.0  % of cases. CONCLUSIONS: In the municipality of Oiapoque, the therapeutic regime used for the treatment of @entity3 @entity1 using @entity2 combined with @entity4 remains effective, when external factors are controlled, such as the quality of anti-malarial drugs, the adhesion to the treatment prescribed, the correct diagnostic and the adjustment of @entity4 dose for @entity0 body weight.

title: Efficacy in the treatment of XXXX by @entity3 in Oiapoque, Brazil, on the border with French Guiana: the importance of control over external factors.

answer: @entity1


abstract: BACKGROUND: Alemtuzumab is a humanized monoclonal antibody approved in several countries for treatment of @entity7 ( @entity7 ). This report summarizes the experience with infusion-associated reactions (IARs) in two phase 3 trials of alemtuzumab in @entity7 and examines skilled nursing interventions in IAR prevention and management. METHODS: In the Comparison of Alemtuzumab and Rebif(  ) Efficacy in @entity2 (CARE-MS) studies, @entity0 with @entity7 (treatment naive [CARE-MS I] or with inadequate response [defined as at least one relapse] to previous therapy [CARE-MS II]) received intravenous infusions of alemtuzumab 12 mg/day on 5 consecutive days at baseline and on 3 consecutive days 12 months later. @entity0 were monitored for IARs during and after each infusion. An IAR was defined as any adverse event occurring during any infusion or within 24 hours after infusion. RESULTS: The IARs affected 90.1% of @entity0 receiving alemtuzumab. The most common IARs were @entity1 , @entity6 , @entity3 , @entity4 , and @entity5 ; most were mild to moderate in severity. Management of IARs consisted of infusion interruption or rate reduction, pharmacologic therapies, and continual @entity0 education and support. Medication administration before and during alemtuzumab infusion reduced IAR severity. Forty-five of 972 alemtuzumab-treated @entity0 (4.6%) required interruption of the first treatment course (ie, infusions did not occur on consecutive days); of these, 24 (53.3%) were still able to complete the first and second full treatment courses. CONCLUSIONS: Nurses played an invaluable role in the detection and management of IARs in the CARE-MS studies. Best practices for management of IARs associated with alemtuzumab include @entity0 and caregiver education, medication to lessen IAR severity, infusion monitoring, and discharge planning.

title: Prevention and Management of Infusion-Associated Reactions in the Comparison of Alemtuzumab and Rebif(  ) Efficacy in XXXX (CARE-MS) Program.

answer: @entity2


abstract: @entity1 of the tibial tuberosity are uncommon injuries that mainly occur in 14 to 16 year-old adolescents involved in sports activities. The mechanism of injury is related to jumping while practicing sports. This retrospective study presents the outcome of @entity1 of the tibial tuberosity in a series of 18 adolescent soccer players treated with the same surgical technique in one center. The hypothesis was that our surgical technique with two parallel screws, one proximal and one distal to the physis, avoids physis injury and has no repercussions on growth. The average age was 14.7 years. All @entity0 were male. The @entity1 included 4 type IIA, 3 type IIB, 6 type IIIA, and 5 type IIIB (Ogden classification). All @entity0 underwent open reduction and internal fixation consisting of screw placement parallel to the joint surface, sparing the tibial physis. There were no complications in any case, and all @entity0 were able to resume their previous sports activities. The technique used appeared to be safe. Screws were removed in 8 @entity0 owing to local discomfort. All @entity0 achieved the same competition level as before the injury.

title: Treatment of XXXX of the tibial tuberosity in adolescent soccer players.

answer: @entity1


abstract: OBJECTIVE: To study the awareness and acceptance of @entity3 ) vaccination among sexually active @entity0 having sex with @entity0 (MSM) and @entity0 not having sex with @entity0 (MNSM) attending the largest @entity1 in Wuxi, China. METHODS: A questionnaire about @entity0 ' socio-demographic characteristics and view on HPV vaccination was collected. RESULTS: A total of 186 MSM and 182 MNSM were recruited. Among MSM, 12.4% were under 20  years old, 64.5% never married and 56.5% from Jiangsu Province (where Wuxi City is located); 64.0% had resided in Wuxi for over 2  years, 64.5% had high school education or more, and 83.9% had an income of 5000 RMB or less per month compared to figures of 5.5%, 50.6%, 73.6%, 54.9%, 86.8% and 64.8% among MNSM, respectively (All P values<0.05). Among these two groups of @entity0 , 18.4% and 23.1% had heard of HPV; 10.2% and 15.4% had heard of HPV vaccine; and 26.2% and 20.2% would take HPV vaccine before sexual debut, respectively. MNSM were significantly more willing to take HPV vaccine than MSM (70.9  vs 34.9%, p<0.001). Factors associated with HPV vaccine acceptance among MSM included engaging mostly in receptive anal sex (Odds ratio (OR)=3.9, 95% Confidence interval (CI): 1.8-13.5), never using a condom in anal sex in the past 6 months (3.5, 1.5-20.2), ever diagnosed with a @entity4 ( @entity4 ) (3.4, 1.3-8.4) and ever receiving @entity2 related services (1.6, 1.1-4.4). Among MNSM these Factors included commercial sex with @entity0 (1.7, 1.2-8.6), never using a condom in commercial sex (1.6, 1.4-7.6) and @entity4 diagnosis (2.0, 1.6-7.3). CONCLUSIONS: Sexually active MSM and MNSM in Wuxi lacked knowledge of HPV and HPV vaccination. The majority of these at-risk @entity0 would not benefit from HPV vaccination as their age at first sex proceeded perceived age of vaccine uptake. Aggressive education aimed at increasing knowledge of HPV and HPV vaccination among these @entity0 is warranted.

title: Awareness and acceptance of XXXX ) vaccination among males attending a major @entity1 in Wuxi, China: A cross-sectional study.

answer: @entity3


abstract: BACKGROUND: Several studies have found that Hispanics and @entity2 have statistically significantly higher adjusted OR for @entity0 screening tests compared to non-Hispanic whites, even though their crude percentages were lower than, or about equal to, those for the non-Hispanic whites. Most documentation is for mammography. This article investigates the prevalence of such unadjusted-to-adjusted "reversed associations" (RA) for @entity1 , colorectal, and prostate testing. We also investigate large percent changes (LPC) to the unadjusted ORs. METHODS: Data were from the 2004/2006/2008 Behavioral Risk Factor Surveillance System (BRFSS) and the 2000/2003/2005/2008 National Health Interview Survey (NHIS). Analyses used a consistent set of covariates. RESULTS: RAs were more common for @entity2 than Hispanics, but Hispanics had a greater number of LPCs. RAs and LPCs occurred more often for Pap testing than colorectal and prostate testing. However, results from the BRFSS and NHIS were often not consistent. CONCLUSIONS: Attention should be given to the National Breast and @entity0 Early Detection Program, as well as public programs addressing other @entity0 , as possible contributors to RAs and LPCs. Hispanics may show more RAs in analyses of future data. Discrepancies between the BRFSS and the NHIS also must be recognized and explained. IMPACT: This research highlights the need for vigilance regarding the results of analyses to identify race/ethnicity as a correlate of @entity0 screening. Results also direct attention to aspects of the results of multivariable analysis other than ORs and confidence intervals.

title: Reversals of association for Pap, colorectal, and prostate cancer testing among XXXX women and men.

answer: @entity2


abstract: BACKGROUND: @entity2 is one of the most commonly prescribed intravenous medications in obstetrics. Despite its widespread use, there are limited data about @entity1 pharmacokinetics, and @entity1 is prescribed empirically without dose adjustment for different indications. OBJECTIVE: The aim of this study was to characterize the pharmacokinetics and placental transfer of @entity2 in pregnant @entity0 and to determine key covariates that impact the pharmacokinetics. STUDY DESIGN: This is a prospective pharmacokinetic cohort study of  pregnant @entity0 who were prescribed @entity2 for preeclampsia, @entity3 , or extreme prematurity. @entity0 received a 4-g loading dose and 2 g/h maintenance dose as clinically indicated. Maternal blood samples were obtained before and at multiple time points during and after @entity1 administration. Cord blood also was sampled at delivery. A population pharmacokinetic approach that used a nonlinear mixed-effects modeling was used to characterize @entity1 disposition. RESULTS: Pharmacokinetic profiles of 111 pregnant @entity0 were analyzed. @entity1 clearance was 3.98 L/h in preeclamptic @entity0 and  5.88 L/h non-preeclamptic @entity0 . Steady-state concentration of  @entity1 was 7.2 mg/dL in preeclamptic @entity0 compared with 5.1  mg/dL in non-preeclamptic @entity0 . Maternal weight significantly impacted time to steady state. The ratio of the mean umbilical vein @entity1 level to the mean maternal serum @entity1 level at the time of delivery was 0.94    0.15. CONCLUSIONS: The study accurately characterizes the pharmacokinetics of @entity1 administered to pregnant @entity0 . Preeclamptic status and maternal weight significantly impact serum @entity1 levels. This pharmacokinetic model could be applied to larger cohorts to help tailor @entity1 treatment and account for these covariates.

title: Pharmacokinetics and placental transfer of XXXX in pregnant @entity0 .

answer: @entity2


abstract: OBJECTIVE: @entity1 that invade the apical chest wall and surrounding structures. Treatment is complex and often involves surgery together with radio- and chemotherapy. We studied the outcome of surgical resection for @entity11 in Iceland. MATERIALS AND METHODS: A retrospective study including all @entity0 that underwent resection of a @entity11 with curative intent in Iceland in the years 1991-2010. Data on symptoms, complications, @entity10 -stage, relapse and survival were analyzed. RESULTS: Twelve @entity0 were operated on; 7 on the right lung. Shoulder @entity3 (n=5) and/or @entity6 (n=3), cough (n=6) and @entity4 (n=5) were the most common presenting symptoms. @entity5 (n=5) and @entity8 (n=4) were the most frequent histological types. Average @entity2 size was 5,9 cm (range: 2,8-15). Five cases were stage IIB and 7 stage IIIA according to operative staging. In 10 cases (83%) the surgical margins were free of @entity2 . All @entity0 survived surgery and only one @entity0 suffered a major operative complication, an @entity7 . In one case induction chemo-radiation prior to surgery was administrated, and 8 @entity0 received postoperative radiotherapy. Recurrent disease was diagnosed in 9 @entity0 ; four had local or regional recurrence, four had distant metastases and one @entity0 was diagnosed with both local and distant recurrences simultaneously. Survival at 5 years was 33% and median survival was 27,5 months (range: 4-181). CONCLUSIONS: Operative and short-term outcomes for @entity0 with @entity11 in Iceland are excellent. However, long-term outcomes are not as favorable and recurrence rate is high compared to other studies, possibly due to incomplete @entity2 and less use of chemo-radiation therapy prior to surgery among these @entity0 . Key words: @entity11 , @entity9 , treatment, outcome, relapse, survival. Correspondence: Tomas Gudbjartsson, tomasgud@landspitali.is.

title: [Outcome of surgical treatment for XXXX in Iceland].

answer: @entity1


abstract: @entity4 based combination chemotherapy remains the mainstay for treatment of advanced @entity1 . The combination of @entity6 and interferon has been found to be effective second line treatment of advanced @entity1 . Hence, we tested the combination of @entity4 , @entity6 and interferon as first line therapy in advanced @entity1 . Eligible @entity0 had to have no prior chemotherapy or interferon. Treatment consisted of @entity4 80 mg/m(2) on day one, followed by @entity6 750 mg/m(2) as a daily infusion for 5 days and @entity9 5 MU/m(2) subcutaneously daily on day 1-5 of @entity6 infusion. Cycles repeated every 21 days. Eighteen @entity0 , of which sixteen were males were enrolled. Median age was 60 years. All @entity0 had @entity7 . The median number of cycles given was 4. Thirteen @entity0 were evaluable for response. Two @entity0 achieved CR and 3 PR for an overall response rate of 28% (95% confidence interval 7% to 49%). Median response duration was 8.3 months. Median survival was 5.5 months. Four @entity0 died secondary to chemotherapy @entity2 . Those were @entity5 in one, @entity8 in one, @entity3 in one and one @entity0 died at home 3 weeks following the third cycle. The above regimen demonstrates excessive @entity2 and moderate activity. It cannot be recommended in its present format. Novel anti- @entity1 agents need to explored.

title: Phase II trial of @entity4 , @entity6 , and XXXX as first line treatment of advanced @entity1 .

answer: @entity9